1. Two phases of HIV RNA decay in CSF during initial days of multidrug therapy. Haas DW, Johnson BW, Spearman P, Raffanti S, Nicotera J, Schmidt D, Hulgan T, Shepard R, Fiscus SA (2003) Neurology 61(10): 1391-6
    › Primary publication · 14638961 (PubMed)
  2. Oxidant stress is increased during treatment of human immunodeficiency virus infection. Hulgan T, Morrow J, D'Aquila RT, Raffanti S, Morgan M, Rebeiro P, Haas DW (2003) Clin Infect Dis 37(12): 1711-7
    › Primary publication · 14689356 (PubMed)
  3. Implications of T-cell P-glycoprotein activity during HIV-1 infection and its therapy. Hulgan T, Donahue JP, Hawkins C, Unutmaz D, D'Aquila RT, Raffanti S, Nicotera F, Rebeiro P, Erdem H, Rueff M, Haas DW (2003) J Acquir Immune Defic Syndr 34(2): 119-26
    › Primary publication · 14526200 (PubMed)
  4. Effects of nelfinavir and its M8 metabolite on lymphocyte P-glycoprotein activity during antiretroviral therapy. Donahue JP, Dowdy D, Ratnam KK, Hulgan T, Price J, Unutmaz D, Nicotera J, Raffanti S, Becker M, Haas DW (2003) Clin Pharmacol Ther 73(1): 78-86
    › Primary publication · 12545146 (PubMed)
  5. Education of physicians-in-training can decrease the risk for vascular catheter infection. Sherertz RJ, Ely EW, Westbrook DM, Gledhill KS, Streed SA, Kiger B, Flynn L, Hayes S, Strong S, Cruz J, Bowton DL, Hulgan T, Haponik EF (2000) Ann Intern Med 132(8): 641-8
    › Primary publication · 10766683 (PubMed)
  6. Increased susceptibility of the sickle cell membrane Ca2+ + Mg(2+)-ATPase to t-butylhydroperoxide: protective effects of ascorbate and desferal. Moore RB, Hulgan TM, Green JW, Jenkins LD (1992) Blood 79(5): 1334-41
    › Primary publication · 1531618 (PubMed)